Author

Armand Assissini

Institutions: Sharp Rees-Stealy Medical Group, Sharp HealthCare

Observed institutions: Sharp Rees-Stealy Medical Group, Sharp HealthCare

ORCID: 0009-0002-7812-396X

Observed ORCID: 0009-0002-7812-396X

OpenAlex ID: A5091923162

Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial

2021 · Maureen G. Maguire, Danni Liu, et al. · JAMA Ophthalmology · 33

Intraocular Pressure–Related Events After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial

2021 · Ahmad A. Aref, Ingrid U. Scott, et al. · JAMA Ophthalmology · 14

Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial

2023 · Steven M. Kymes, Neal L. Oden, et al. · JAMA Ophthalmology · 10

Baseline Characteristics and Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18

2022 · Ingrid U. Scott, Neal L. Oden, et al. · JAMA Ophthalmology · 6

Digital Health Support for Cataract Surgery With the Sharp Health Companion CareKit App: Randomized Controlled Trial

2026 · Tommy S Korn, Armand Assissini, et al. · JMIR mhealth and uhealth · 2

Works count: 5

Citation count: 65

H-index: 4

I10-index: 3